Summary of Seer Inc. Conference Call Company Overview - **Company**: Seer Inc. - **Industry**: Tools and diagnostics in the healthcare sector Key Points and Arguments Company Performance and Growth - Seer experienced substantial growth in 2025, with a **67% increase** in install base, reaching **82 instruments** [5] - Year-over-year consumable volume increased by **70%** [5] - Publications from customers rose from approximately **35** to **76**, with many appearing in high-impact journals [5] - Seer successfully conducted three population-scale studies using deep unbiased proteomics, with sample sizes of **10,000+** and **20,000+** [6] Product Development and Innovation - Launched the **Proteograph ONE Assay** in June 2025, which significantly improved operational efficiency by reducing runtime from **8.5 hours to 4.5 hours** and increasing throughput to **80 samples per run** [6][7] - The company aims for revenue growth of **50% to 100%** annually, emphasizing the need to build a market for their product [8] Market Strategy and Customer Engagement - Introduced the **Seer Technology Access Center (STAC)** to lower barriers for customer adoption, with **50%** of the install base in 2025 being previous STAC users [12] - The **Strategic Instrument Replacement Program (SIP)** allowed customers to test instruments with a significant upfront consumable purchase, leading to a **60% conversion rate** from loans to purchases [13] - Addressed bottlenecks in unbiased proteomics through various upgrades, including the **Proteograph Analysis Suite** [14] Financial Outlook and Market Challenges - Guidance for 2026 anticipates total revenue between **$16 million and $18 million**, with a growth rate of **3%** at the midpoint [9] - The company faces challenges from funding constraints in the academic market and NIH, impacting customer budgets [16][42] - Despite these challenges, discussions with population-scale cohorts are ongoing, indicating potential for future revenue growth [16] Competitive Landscape - Seer claims to have a unique position in the protein enrichment space, with over **200 patents** supporting their technology [45] - Competitors are noted to be inferior in performance, as evidenced by customer publications [45] - Seer emphasizes the importance of innovation over competition, focusing on moving the goalpost forward [45] Future Developments - A new detector, purpose-built for deep unbiased proteomics, is expected to change the landscape of the field, with data to be shared in the second half of the year [33][35] - The company remains optimistic about future growth, with a strong belief in the value of their technology and its potential impact on the market [48] Additional Important Insights - The company has maintained a **low operational expenditure (OpEx)** while investing in innovation, demonstrating financial discipline [37] - The gross margin is currently in the low **50% range**, with consumables driving the majority of profitability [18] - Seer is committed to competitive pricing to facilitate adoption, particularly in population studies, while ensuring the value of their offerings is recognized [19] This summary encapsulates the key insights from Seer Inc.'s conference call, highlighting the company's growth, product innovations, market strategies, and future outlook in the diagnostics industry.

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $4.1 million, representing a 2% increase compared to $4 million in Q3 2024, primarily due to higher product and service revenue [22][24] - Gross profit for Q3 2025 was $2.1 million, with a gross margin of 51%, compared to $1.9 million and 48% in Q3 2024 [24] - Net loss for Q3 2025 was $18.2 million, an improvement from a net loss of $21.3 million in Q3 2024 [25] - The company ended the quarter with approximately $251 million in cash, cash equivalents, and investments, sufficient to reach cash flow breakeven [27] Business Line Data and Key Metrics Changes - Product revenue for Q3 2025 was $2.8 million, consisting of sales of Proteograph instruments and consumable kits [23] - Service revenue was $1.2 million for Q3 2025, including $300,000 of related party revenue, primarily from STACC service projects [23] - More than two-thirds of instrument shipments in Q3 were acquired by customers who had previously accessed STACC, indicating strong customer interest [24][19] Market Data and Key Metrics Changes - The company shipped just under three times as many instruments in the first nine months of 2025 compared to all of 2024, reflecting strong demand for the Proteograph [5][18] - The company continues to face headwinds from budget constraints and uncertainty around government funding, particularly related to NIH [28][39] Company Strategy and Development Direction - The company is focused on advancing the reach and impact of the Proteograph platform, with a strong emphasis on product innovation and enabling large cohort studies [4][6] - The Proteograph One assay represents a significant advancement, allowing for over 1,000 samples per week and improving precision [8] - The company is actively pursuing partnerships, such as with Thermo Fisher Scientific, to enhance market presence and drive adoption of the Proteograph [20][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the value proposition of the Proteograph despite challenges from government shutdowns and funding uncertainties [5][14] - The company anticipates full-year revenue to be in the range of $17-$18 million for 2025, representing growth of 24% at the midpoint over 2024 [28] - Management highlighted the increasing momentum in customer publications and large-scale studies, indicating a positive trend for future growth [29][38] Other Important Information - The company has repurchased approximately $22 million of Class A common shares, reducing net total shares outstanding by approximately 14% [5][26] - The 2025 Seer Insights Grant Program received 88 applications, more than double from the previous year, indicating strong interest in proteomics research [21] Q&A Session Summary Question: Update on the partnership with Thermo Fisher Scientific - The partnership is progressing well, with two joint opportunities closed in the quarter and a pipeline of opportunities being pursued [31][32] Question: Potential for more large-scale studies in the future - The introduction of the Proteograph Product Suite has enabled large-scale studies that were previously not feasible, with ongoing discussions for even larger studies [34][35] Question: Trends among academic customers and spending outlook - Despite challenges from government shutdowns, there is increasing interest from academic customers, with 40% of revenue year-to-date coming from academic and government customers [39][40]